These findings provide a molecular framework for the previous observation that USP9x is downregulated in pancreatic ductal adenocarcinoma (PDA) [20] and for the finding, presented here, that low levels of USP9x expression correlate with poor prognosis in renal clear cell carcinoma (ccRCC). This evidence concerns the gene USP9X and Patent ductus arteriosus.